The validity of rheumatoid arthritis diagnoses in Finnish biobanks
Authors' conclusion
These results demonstrate that the validity of RA diagnoses in Finnish biobanks was good and can be further improved by including data on special reimbursement for medication, number of visits, and serological data.
Study context
- Population
- Finnish biobank participants from five biobank hospitals in Finland
- Participants
- 500 participants
- Comparison
- Care Register for Health Care (CRHC) diagnostic codes and special reimbursement data vs rheumatologist review of medical records
- Seropositive rheumatoid arthritis (RA)n = 125
- Seronegative RAn = 125
- Controlsn = 250reference
- Outcome
- Validity (PPV) of RA diagnoses in Finnish biobanks
Methodological detailsmedical record review by a rheumatologist, age- and gender-matched controls, five biobank hospitals
- Medical record review by a rheumatologist
- Age- and gender-matched controls
- Five biobank hospitals
Performance
As reported in the abstract
PPV of CRHC diagnosis of RA (seropositive and seronegative combined)
PPV, CRHC diagnosis of RA
0.82
PPV, with special reimbursement for anti-rheumatic medications for RA
0.89
Further findings
PPV of CRHC diagnosis of RA by number of visits
- One visit
- 0.82
- Two visits
- 0.85
- Five visits
- 0.89
- Ten visits
- 0.90
- PPV higher in patients with more than one visit
PPV by number of visits, patients also with special reimbursement for anti-rheumatic medication
- One visit
- 0.89
- Two visits
- 0.91
- Five visits
- 0.93
- Ten visits
- 0.94
PPV in patients with special reimbursement for anti-rheumatic medications for RA
- PPV
- 0.89
PPV in ACPA-positive patients
- PPV
- 0.98
Original publication
The validity of rheumatoid arthritis diagnoses in Finnish biobanks. Scand J Rheumatol. Published 13 October 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →